Hawai'i is among 32 states and the District of Columbia that will share in a $62 million payment by Eli Lilly and Co., which made the payment in resolving an investigation relating to the sales, marketing and promotion of the antipsychotic medication Zyprexa.

Lilly said there was no finding that it violated any provision of state laws and that Zyprexa remains available t patients and on formularies for Medicaid programs in all 50 states and Washington.

"We believe all of the parties involved share an interest in putting this dispute behind us," said Robert A. Armitage, Lilly senior vice president and general counsel in a news statement.